Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Guardant Health Inc
(NQ:
GH
)
28.38
+0.43 (+1.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Guardant Health Inc
< Previous
1
2
3
4
5
6
Next >
Guardant Health to Report First Quarter Financial Results on May 5, 2022
April 13, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
April 11, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
April 04, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
March 17, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
March 14, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
February 23, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
February 07, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
February 01, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
January 19, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
January 18, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
January 07, 2022
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
December 29, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
December 17, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
December 06, 2021
From
Guardant Health, Inc.
Via
Business Wire
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
November 11, 2021
From
Guardant Health, Inc.
Via
Business Wire
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
November 11, 2021
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...
Via
FinancialNewsMedia
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
November 08, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Third Quarter 2021 Financial Results
November 04, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
November 03, 2021
From
Guardant Health, Inc.
Via
Business Wire
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
October 25, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Appoints Myrtle Potter to Its Board of Directors
October 20, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
October 08, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
October 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
September 15, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
August 06, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
August 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Second Quarter 2021 Financial Results
August 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
July 20, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
July 13, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
June 22, 2021
From
Guardant Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.